A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Latest Information Update: 20 Jan 2026
At a glance
- Drugs Olpasiran (Primary)
- Indications Cardiovascular disorders
- Focus Registrational; Therapeutic Use
- Acronyms OCEAN(a)-CCTA
- Sponsors Amgen
Most Recent Events
- 25 Dec 2025 New trial record